The European Society for Medical Oncology (ESMO)
ESMO Symposium on Immuno-Oncology 2014 Organisation
1OROLE OF PDL1 EXPRESSION AND TUMOR INFILTRATING LYMPHOCYTES (TILS) IN GLIOBLASTOMA (GBM) AND BRAIN METASTASES (BM)
2OACTIVATION OF T CELLS UPON TREATMENT WITH BISPECIFIC ANTIBODIES CORRELATES WITH THE EXPRESSION OF CO-INHIBITORY RECEPTORS ON TUMOR-INFILTRATING LYMPHOCYTES IN HUMAN LUNG CANCER
3OLONG-TERM MAINTENANCE THERAPY WITH THE TLR-9 AGONIST MGN1703 IN A SUBGROUP OF METASTATIC COLORECTAL CANCER PATIENTS FROM THE IMPACT STUDY
4OEVALUATING THE PLACE OF INTERLEUKIN-2 IN THE MANAGEMENT OF METASTATIC RENAL CELL CANCER (MRCC) IN THE ERA OF TARGETED THERAPY
5PMICROTUBULE-DEPOLYMERIZING AGENTS USED IN ANTIBODY-DRUG-CONJUGATES INDUCE ANTITUMOR ACTIVITY BY STIMULATION OF DENDRITIC CELLS
6PINVESTIGATION OF THE HELICASE ANTIGEN (HAGE) AS IMMUNOTHERAPEUTIC TARGET FOR BREAST CANCER THERAPY
7PCOMBINATION OF CETUXIMAB WITH RADIOIMMUNOTHERAPY SIGNIFICANTLY ENHANCES THERAPEUTIC RESPONSE IN COLORECTAL CANCER
8PSAFETY OF IMPRIME PGG, A NOVEL INNATE IMMUNE MODULATOR, IN ADULTS WITH STAGE IV NON-SMALL CELL LUNG CANCER (NSCLC)
9PLOW DOSES OF CISPLATIN CAN HELP DENDRITIC CELL VACCINES TO REDUCE IMMUNOSUPPRESSION IN TUMOR MICROENVIRONMENT
10PINFLUENCE OF TUMOR NECROSIS FACTOR-ALPHA-THYMOSIN-ALPHA1 ON THE HUMORAL AND CELLULAR IMMUNITY OF PATIENTS WITH LOCALLY ADVANCED BREAST CANCER
11PADVANCING APOPTOSIS BY MIR-122-5P IN COMBINATION WITH TRASTUZUMAB IN SKBR3 CELL LINE
12PLECTIN GALACTOSIDE-BINDING SOLUBLE 3 BINDING PROTEIN (LGALS3BP) IS A CANCER-ASSOCIATED LIGAND FOR INHIBITORY SIGLECS
14PCOMPARATIVE ANALYSIS OF TUMOR PLOIDY AND LOCAL IMMUNITY IN GUT CANCER
15PSIGNIFICANCE OF MYOFIBROBLAST APPEARANCE AT THE INVASIVE FRONT IN EARLY-STAGE (T1/T2) ORAL SQUAMOUS CELL CARCINOMA (OSCC) : A PRELIMINARY REPORT
13PSTATUS OF IMMUNE SYSTEM OF PATIENTS WITH ENDOMETRIAL CANCER IN DEPENDENCE ON THE DISEASE STAGE
16TiPA PHASE 3, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, INTERNATIONAL STUDY OF MEDI4736 IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE NSCLC (STAGE III) WHO HAVE NOT PROGRESSED FOLLOWING PLATINUM-BASED, CONCURRENT CHEMORADIATION THERAPY (PACIFIC)
17TiPA PHASE 2, NON-COMPARATIVE, OPEN-LABEL, INTERNATIONAL STUDY OF MEDI4736 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PD-L1-POSITIVE NSCLC (STAGE IIIB-IV) WHO HAVE RECEIVED ≥ 2 PRIOR SYSTEMIC TREATMENT REGIMENS (ATLANTIC)
18TiPDESIGN OF A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN (SGN-35) AS SALVAGE THERAPY FOR MALES WITH CHEMORESISTANT GERM-CELL TUMORS (GCT)
19TiPA PHASE 2 STUDY OF DOCETAXEL IN COMBINATION WITH INDOXIMOD FOR METASTATIC BREAST CANCER
author index
drug index
translational research index